Over 200,000 pounds of liquid egg products recalled over possible contamination
Over 200,000 pounds of liquid egg products recalled over possible contamination
Show Caption
Hide Caption
Egg prices not dropping fast enough for consumers
Farmers are dropping egg prices but the trickle down effect hasn't made its way to the consumer yet as millions of eggs are still being imported from other countries.
Fox - 10 Phoenix
More than 200,000 pounds of liquid egg products have been recalled over a potential contamination of cleaning solution.
In an announcement from the U.S. Department of Agriculture's Food Safety and Inspection Service on Friday, Cargill Kitchen Solutions recalled more than 212,000 pounds of liquid egg products, saying they say they could contain sodium hypochlorite, a product commonly used in bleach.
The inspection service says that the recalled products were produced on March 12 and 13 and had use-by dates of Aug. 9 and 10 this year, as well as March 7, 2026.
The recalled products include variations of the Egg Beaters brand, as well as the Bob Evans brand of liquid eggs.
The products were shipped to Ohio and Texas, as well as 'for foodservice use in Arizona, California, Colorado, Florida, Illinois and Iowa.'
'Consumers who have purchased these products are urged not to consume them and food service locations are urged not to serve them. These products should be thrown away or returned to the place of purchase,' the agency said.
What products were recalled?
The following products were included as part of the recall, according to the agency:
32-ounce (2-pound) carton containing egg beaters original liquid egg substitute with a use-by date of Aug. 10, 2025.
32-ounce (2-pound) carton containing egg beaters cage-free original liquid egg substitute with a use-by date of Aug. 9, 2025.
32-ounce (2-pound) carton containing egg beaters cage-free original frozen egg substitute, or in Spanish, egg beaters no enjauladas original sustituto de huevo congelado, with a use-by date of March 7, 2026.
32-ounce (2-pound) carton containing Bob Evans Better'n Eggs made with real egg whites with a use-by date of Aug. 10, 2025.
Fernando Cervantes Jr. is a trending news reporter for USA TODAY. Reach him at fernando.cervantes@gannett.com and follow him on X @fern_cerv_.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 hours ago
- Yahoo
SpliceBio lands $135M for a new kind of eye gene therapy
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. SpliceBio, a Spanish biotechnology company working on next-generation gene therapies, said Wednesday it raised $135 million in a Series B round to advance its lead program in Stargardt disease into further clinical testing. The startup is built around a technology that's meant to overcome a key limitation of current gene therapies. Scores of gene therapy developers use adeno-associated viruses, or AAVs, to deliver genetic cargo into the body. But because of their small size, AAVs can't carry larger corrective genes, leaving many diseases out of reach or forcing companies to come up with creative solutions. One example is in Duchenne muscular dystrophy. Because of the large size of the gene coding for the muscle-protecting protein dystrophin Duchenne patients lack, several companies, like Sarepta Therapeutics, have developed gene therapies that make a shortened form. The approach comes with drawbacks, however, as a truncated version of the protein might not work as well as the original. SpliceBio has a different workaround. The company is using two separate AAVs to send pieces of a large gene into cells. Once inside, specially engineered splicing molecules help reassemble their cargo into full-length proteins. Stargardt disease, for example, is caused by mutations to the ABCA4 gene, which is too large to stuff into an AAV. SpliceBio says its method can help the body produce a functional version of the protein that gene produces. Its lead program, SB-007, is in a Phase 1/2 trial. SpliceBio isn't the only biotech pursuing this type of approach to treat Stargardt, an inherited eye condition that causes progressive vision loss. Another European company, AAVantgarde, has a similar type of program in early-stage testing. SpliceBio's technology is based on research conducted at Princeton University, where co-founder and CEO Miquel Vila-Perelló was studying protein design and engineering. Launched in 2014 under the name ProteoDesign, the biotech is also working on additional programs in ophthalmology, neurology and other undisclosed therapeutic areas. Its Series B round was co-led by EQT Life Sciences and Sanofi Ventures, and involved seven other backers including Roche Venture Fund, New Enterprise Associates and Novartis Venture Fund. "The support from such high-quality investors underscores the strength of our programs and our unique protein splicing platform and its potential to unlock gene therapies for diseases that remain untreatable today,' Vila-Perelló said in a statement. The company raised €50 million in a Series A round in 2022. Gene and cell therapy startups backed by the roughly two dozen investment firms BioPharma Dive tracks have secured a little over $1.1 billion in venture dollars so far in 2025. Half of those fundings have come in the form of 'megarounds' exceeding $100 million apiece, continuing an ongoing trend. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
9 hours ago
- Yahoo
Centre for Neuro Skills Unveils New Website Design to Better Serve Brain Injury Patients and Their Families
BAKERSFIELD, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- Centre for Neuro Skills (CNS), a leader in traumatic brain injury and stroke rehabilitation services, today announced the launch of its completely redesigned website at The revamped website features an intuitive, user-friendly interface designed to better serve patients, families, healthcare professionals and caregivers seeking information and resources for brain injury rehabilitation. The redesign incorporates the visual elements and messaging from CNS' recent 'ReThink Rehab' advertising campaigns, creating a cohesive brand experience across all platforms. Reimagined Digital Experience The new site design reflects the organization's commitment to challenging the status quo in brain injury rehabilitation with its powerful message 'ReThink Rehab,' capturing the essence of CNS' mission to reduce disability and maximize independence. "Our new website is more than just a visual upgrade—it's a reflection of our unwavering belief in the ongoing potential for recovery in brain injury patients," said Ben Ashley, Associate Vice President of Marketing and Communications at CNS. "We've created a digital space that embodies our vision while making it easier for those we serve to access the information and support they need." Key Features of the New Website: Enhanced User Navigation: Simplified menus and intuitive pathways guide visitors to essential information about CNS' services, patient success stories and educational resources. Patient Journey Showcase: Interactive elements highlight real patient experiences, demonstrating how CNS' approach challenges the notion of plateauing in brain injury recovery. Resource Hub: Expanded educational materials for patients, families and healthcare providers that support the ongoing journey of brain injury recovery. Responsive Design: Fully optimized experience across all devices, ensuring accessibility for users regardless of how they access the site. This includes the option to translate the entire site into Spanish with just a click and a fully integrated accessibility tool for those who may need specific cognitive or visual assistance. A Curated User Experience: New, dynamic content added to the site now makes it easier for site visitors to find content and stories most relevant to them. Integrated Campaign Elements: The site seamlessly incorporates visuals and messaging from CNS' recent "ReThink Rehab" initiative, the first advertising campaign in the organization's 45-year history, reinforcing the powerful narrative that recovery continues beyond conventional expectations with personalized therapies. About the "Patients Don't Plateau" Philosophy At the core of the website redesign is CNS' foundational belief that brain injury recovery is not limited by arbitrary timelines. This philosophy, featured prominently throughout the new site, challenges the conventional narrative that patients will reach a "plateau" in their recovery after a certain period. "For too long, brain injury patients have been told that their recovery has an endpoint," explained David Harrington, President and CEO of CNS. "Our new website amplifies our message that with the right approach and continued therapeutic innovation, patients can continue making meaningful progress throughout their lives and achieve independence." CNS, now in its 45th year, was recently named one of Newsweek's 'America's Greatest Midsize Workplaces for 2025.' Of all neurorehabilitation providers listed in the healthcare category, CNS is the only one who achieved a 5-star rating. About Centre for Neuro Skills Named by Newsweek as 'America's Greatest Midsize Workplaces for 2025,' Centre for Neuro Skills is an experienced and respected world leader in providing intensive rehabilitation and medical programs for those recovering from all types of brain injury. CNS covers a full spectrum of advanced care from residential and assisted living to outpatient/day treatment. Founded by Dr. Mark Ashley in 1980, CNS has seven locations in California and Texas. For more information about Centre for Neuro Skills, visit: Facebook, Twitter, LinkedIn, YouTube. Media, please note: Visual assets, including photos, are available. To request an interview with CNS leadership or clinical staff, please contact Robin Carr at 415.766.0927 or CNS@ Media Contact:Robin CarrLandis Communications Inc.415.766.0927CNS@ A photo accompanying this announcement is available at
Yahoo
11 hours ago
- Yahoo
Oxfordshire hospitals' most requested language interpreter revealed
The most requested language interpretation service at Oxfordshire's hospitals is not French, Spanish, Mandarin Chinese nor Arabic. Instead, a recent freedom of information request to the Oxfordshire NHS Foundation Trust has revealed that it is Portuguese. The trust provides physical, mental health and social care for people of all ages across Oxfordshire, Buckinghamshire, Swindon, Wiltshire, Bath and Somerset. Its responsibilities include Abingdon, Bicester, Wallingford, Wantage and Witney community hospitals, as well as numerous other services such as disability and dental care. READ MORE: That Portuguese is the most sought-after translation service tallies with data from the latest Census (2021) which reported that it was second – after English – as the most spoken primary language by residents of Oxford, narrowly beating Spanish and Polish. As well as revealing the most requested language interpretation service for the trust, the freedom of information request showed how much is being spent on interpretation as a whole. Witney Community Hospital falls under the Oxfordshire NHS Foundation Trust For the latest year-long period (2024-25) this was £185,659, significantly down from the same time a year before (2023-24) when it was £211,003. It is also reduced from the timeframe before that (2022-23) when £204,475 was spent on translation across the trust. Missed a copy of the Oxford Mail you wanted? Here's what to do — Oxford Mail (@TheOxfordMail) May 13, 2024 This comes after the Daily Mail revealed that the NHS has spent almost £80 million on language and interpretation services since 2020 for patients – not just for non-English speakers but also the hard of hearing and blind people. Responding to the paper, an NHS spokesperson said: 'Translation and interpretation services are a legal requirement and essential to deliver effective and safe patient care. 'It is right the NHS offers these services for those who need them, including translations, sign language and documents.' Even so, the money spent on translation services nationally has led to criticism from some MPs and groups such as the Taxpayers' Alliance.
